# Complix NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/complix

- Industry: Biotechnology
- Headquarters: Belgium
- Website: http://www.complix.be
- Total disclosed funding: $27M
- Latest round: Series B (Jun 26, 2013)
- Investors on record: 10

## About

Founded in 2008 and based in Belgium, Complix NV operates as a biopharmaceutical company that focuses on developing Alphabody-based therapeutics for the treatment of oncology and autoimmune diseases.

## Funding rounds

- Series B, Jun 26, 2013, $15M — K.U. Leuven Research & Development, Andera Partners, Gimv, Omnes Capital, Koramic Investments, LRM, Vesalius Biocapital, Baekeland Fonds, PMV, Biotech Fund Flanders
- Series A, Jan 12, 2011, $6.7M — Omnes Capital
- Series A, Jun 10, 2010, $2.3M — LRM, Vesalius Biocapital
- Seed, Jun 1, 2008, $2.8M — Koramic Investments, Baekeland Fonds, PMV

## Investors

- Koramic Investments — Seed, Series B
- Baekeland Fonds (https://capitalatlas.ai/funds/baekeland-fonds) — Seed, Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Seed, Series B
- LRM (https://capitalatlas.ai/funds/lrm) — Series A, Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A, Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B
- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B
- Biotech Fund Flanders — Series B